bluebird bio (BLUE) PT Set at $122.00 by Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald set a $122.00 price target on bluebird bio (NASDAQ:BLUE) in a research report released on Friday. The brokerage currently has a hold rating on the biotechnology company’s stock.

A number of other analysts have also issued reports on the company. Svb Leerink lowered bluebird bio from an outperform rating to a market perform rating in a research report on Tuesday, March 5th. Leerink Swann lowered bluebird bio from an outperform rating to a market perform rating and set a $150.00 target price on the stock. in a research report on Tuesday, March 5th. They noted that the move was a valuation call. ValuEngine raised bluebird bio from a hold rating to a buy rating in a research report on Friday, March 1st. Cowen assumed coverage on bluebird bio in a research report on Tuesday, February 26th. They set an outperform rating and a $149.91 target price on the stock. Finally, SunTrust Banks dropped their target price on bluebird bio to $184.00 and set a buy rating on the stock in a research report on Monday, February 25th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $168.12.

Shares of NASDAQ BLUE opened at $146.22 on Friday. bluebird bio has a 1 year low of $87.49 and a 1 year high of $199.70. The stock has a market cap of $7.89 billion, a PE ratio of -13.69 and a beta of 2.64.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.83) by $0.11. bluebird bio had a negative return on equity of 32.15% and a negative net margin of 1,018.02%. The business had revenue of $19.20 million for the quarter, compared to analyst estimates of $9.06 million. During the same period in the previous year, the company earned ($2.52) earnings per share. The company’s revenue for the quarter was up 357.1% compared to the same quarter last year. As a group, research analysts predict that bluebird bio will post -11.81 EPS for the current year.

In other bluebird bio news, insider Nick Leschly sold 7,374 shares of bluebird bio stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $113.64, for a total value of $837,981.36. Following the completion of the transaction, the insider now directly owns 20,682 shares in the company, valued at $2,350,302.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kory James Wentworth sold 209 shares of bluebird bio stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $125.96, for a total value of $26,325.64. Following the completion of the transaction, the insider now owns 4,403 shares of the company’s stock, valued at $554,601.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,438 shares of company stock valued at $5,486,744. 3.00% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of BLUE. Private Advisor Group LLC boosted its stake in bluebird bio by 41.7% in the third quarter. Private Advisor Group LLC now owns 3,398 shares of the biotechnology company’s stock valued at $496,000 after acquiring an additional 1,000 shares during the period. Wells Fargo & Company MN grew its holdings in bluebird bio by 4.2% in the 3rd quarter. Wells Fargo & Company MN now owns 70,117 shares of the biotechnology company’s stock worth $10,237,000 after buying an additional 2,798 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in bluebird bio in the 3rd quarter valued at approximately $239,000. SG Americas Securities LLC acquired a new stake in bluebird bio in the 3rd quarter valued at approximately $214,000. Finally, Rhumbline Advisers increased its position in bluebird bio by 5.2% in the 3rd quarter. Rhumbline Advisers now owns 56,415 shares of the biotechnology company’s stock valued at $8,237,000 after acquiring an additional 2,806 shares during the period.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

See Also: Bid-Ask Spread

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Anticipate TD Ameritrade Holding Corp.  Will Post Quarterly Sales of $1.46 Billion
Analysts Anticipate TD Ameritrade Holding Corp. Will Post Quarterly Sales of $1.46 Billion
TravelNote Price Reaches $0.0135 on Exchanges
TravelNote Price Reaches $0.0135 on Exchanges
$70.00 Million in Sales Expected for Primo Water Co.  This Quarter
$70.00 Million in Sales Expected for Primo Water Co. This Quarter
UralsCoin Trading Down 3.6% Over Last Week
UralsCoin Trading Down 3.6% Over Last Week
Cruisebit Price Hits $0.0085 on Top Exchanges
Cruisebit Price Hits $0.0085 on Top Exchanges
IHT Real Estate Protocol  Trading 23.5% Lower  Over Last 7 Days
IHT Real Estate Protocol Trading 23.5% Lower Over Last 7 Days


© 2006-2019 Ticker Report